Adverse reactions to SGLT-2 inhibitors in children with diabetes mellitus
- 12 August 2025
- journal article
- Published by PANORAMA Publishing House in Terapevt (General Physician)
- No. 8,p. 46-53
Abstract
The purpose of the study: to conduct an expert assessment of post-registration data from real clinical practice on the safety of SGLT-2 inhibitors in children. Objectives of the study: to establish quantitative and qualitative characteristics of adverse reactions (ARs) when using SGLT2 inhibitors in children. Conclusion: The results of the analysis of real clinical practice data on the safety of SGLT-2 inhibitors in children suggest a large volume of consumption of these drugs, which can be indirectly indicated by the number of cases presented. Differences from adults in the structure of use and in the manifestations of side effects were established. Practical recommendations: It is necessary to take into account the established risks when using SGLT-2 inhibitors in children, since they can cause serious adverse reactions and require attention from pediatricians and parents, until regulatory authorities have approved the corresponding changes to the instructions for medical use of these drugs.Keywords
This publication has 6 references indexed in Scilit:
- Renal glucosuria in childrenWorld Journal of Clinical Pediatrics, 2025
- Main epidemiological indicators of type 1 diabetes mellitus in children in the Russian Federation for 2014–2023Problems of Endocrinology, 2024
- Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in children and young adults: a systematic review and meta-analysisAnnals of Pediatric Endocrinology & Metabolism, 2024
- Epidemiology and Clinical Features of Arterial Hypertension in Patients with Type 2 Diabetes Mellitus. Literature ReviewThe Russian Archives of Internal Medicine, 2024
- Clinical studies of dapagliflozin in pediatric patients: a rapid reviewAnnals of Pediatric Endocrinology & Metabolism, 2022
- Multi-Faceted Influence of Obesity on Type 1 Diabetes in Children – From Disease Pathogenesis to ComplicationsFrontiers in Endocrinology, 2022